Research Study for those with NASH/Fatty Liver Disease

IRB/UVA Tracking #
21775
Principal Investigator
Stephen H Caldwell
Contact
Jennifer Greene
Contact Email
Contact Phone
434.982.0709
Official Trial Title
A Phase 3, Multinational, Double Blind, Randomised, Placebo Controlled Study of MGL-3196 (resmetiron) in Patients with Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/0r Hepatic Decompensation
Study Description

The Hepatology Department seeks adults over 18 with NASH (fatty liver disease) for a research study. The purpose of the study is see if a medication called resmetiron safe and effective in treating fatty liver disease.

You may be eligible for this study if you have fatty liver disease, meet certain lab criteria and can have a MRI and DXA (bone) scans.

Study involves taking an experimental study medication by mouth daily, having a liver biopsy at the beginning of the study and after one year of treatment, having an MRI and DXA (bone scan) at the beginning of treatment. Study may last up to 5 years.

Study-related exams, tests and experimental medication provided free of charge.

Compensation

You will be paid $75 for each visit that you complete.